Navigation Links
Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
Date:10/18/2007

Top Line Results of Phase II Study in Previous Nonresponders also Reported

KENILWORTH, N.J., Oct. 18 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today provided an update on the clinical development program for boceprevir, its investigational oral hepatitis C protease inhibitor. Initial results from an ongoing Phase II study in treatment-naive (previously untreated) hepatitis C patients showed boceprevir (800 mg TID) in combination with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) achieved a high rate of early virologic response, with up to 79 percent of patients having undetectable virus (HCV-RNA) at week 12 of boceprevir treatment compared to 34 percent of patients receiving PEGINTRON and REBETOL alone.

"These initial results, while preliminary, are very encouraging, and showed that boceprevir is a potent antiviral agent for hepatitis C," said Paul Kwo, M.D., associate professor of medicine and medical director, liver transplantation, Department of Medicine, Division of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, and the lead investigator of the study. "In this study, boceprevir improved viral clearance rates at week 12 in genotype 1 hepatitis C infection compared to the control group. We look forward to further results from this ongoing study."

Boceprevir is being evaluated in combination with PEGINTRON and REBETOL for the treatment of patients chronically infected with hepatitis C virus (HCV) genotype 1 in two large Phase II clinical studies, in which more than 800 patients have received boceprevir. One study involves treatment-naive patients and the other involves patients who were nonresponders to previous peginter
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
2. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
5. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
6. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
7. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
8. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
9. Sygnis Pharma AG announces date for presentation of clinical results
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... and sometimes uncomfortable colonoscopies may soon be a thing ... of a new screening test that is making its ... EDP Biotech Corporation (EDP) is pursuing a ... doctors can use to screen for colon cancer with ... 30% of colon cancer deaths are avoidable by early ...
(Date:12/14/2009)... Seven leading cancer physicians ... Oncology Research participated in studies ... 2009 San Antonio Breast Cancer ... the Henry B. Gonzalez Convention ... . Fifteen others presented their ...
(Date:12/14/2009)... Calif., Dec. 14 Alexza Pharmaceuticals, Inc. (Nasdaq: ... its New Drug Application (NDA) for Staccato® loxapine (AZ-004) ... AZ-004 is an inhalation product candidate being developed for ... or bipolar disorder. The IND for Staccato ... 2005. ,, "AZ-004 has delivered a predictable and consistent ...
Breaking Medicine Technology:EDP Biotech Takes Next Step in the Development of ColoMarker 2EDP Biotech Takes Next Step in the Development of ColoMarker 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6Dr Alan F Dowling Named AHIMAs Next Chief Executive Officer 62460 1Dr Alan F Dowling Named AHIMAs Next Chief Executive Officer 62460 2Ministerial Roundtable Discusses Future of Medical Tourism 62455 1Ministerial Roundtable Discusses Future of Medical Tourism 62455 2Ministerial Roundtable Discusses Future of Medical Tourism 62455 3Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 1Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 2Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 3Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 4
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), a ... product candidates principally,for use in the hospital setting, ... nine months ended September 30, 2008., The ... development,programs for its two Phase III product candidates ...
... November 6 Bavarian,Nordic has completed a clinical safety ... HIV infected subjects that confirms the excellent,safety profile of ... this study will be submitted to the FDA and ... the RFP-3 contract. The clinical safety,report constitutes a major ...
Other Medicine Technology:Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 2Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 3Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 4Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 5Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 6Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 7Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 8Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R) 2
(Date:12/15/2009)... Synthetic Fillers and Large Volume Injections Dangerous , ... ... -- The popularity and hype surrounding buttock augmentation and other ... outside U.S. borders is an alarming and potentially deadly trend, ... Permanent fillers such as polymethylmethacrylate (PMMA), silicone, and polyacrylimide used ...
(Date:12/15/2009)... Seattle, WA) – Delicious Planet, Seattle’s premier organic meal delivery ... launch of its Delicious Planet Detox Program, Randi Carter, company ... ... (December 15, 2009 – Seattle, WA) – Delicious ... is accepting orders now for the launch of its Delicious ...
(Date:12/15/2009)... HONG KONG, Dec. 15 /PRNewswire-Asia/ --, Key points:, ... Cells (South) Company, Limited with ... exclusive access to about 1 million new births, ... -- CordLife,s geographical footprint in Asia Pacific is enlarged, with, ... India, two of the largest and fastest, ...
(Date:12/15/2009)... out-of-pocket costs for beneficiaries based on health status categories and ... ... Antonio, TX (Vocus) Dec. 14, 2009 -- Physicians Health Choice ... recognized for cost-sharing effectiveness and value in the design of ... Medicare beneficiaries. The Medicare Advantage company won for its ...
(Date:12/15/2009)... , ... (PRWEB) December 10, 2009 -- Millions of men and women suffer ... clusters of red, blue or purple veins that spider-web across the nose, ... US, it’s been estimated that 25-30% of women and 10-20% of men ... Veinwave has been available for over 8 years in Europe ...
Breaking Medicine News(10 mins):Health News:Physicians Coalition for Injectable Safety Warns Buttock-Boosting Injections Risky and Deadly 2Health News:Physicians Coalition for Injectable Safety Warns Buttock-Boosting Injections Risky and Deadly 3Health News:Physicians Coalition for Injectable Safety Warns Buttock-Boosting Injections Risky and Deadly 4Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 2Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 3Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 4Health News:CordLife Secures Strategic Presence in China 2Health News:CordLife Secures Strategic Presence in China 3Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 2Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 3Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 4Health News:Vein Center & CosMed, Inc. Selected as Exclusive St. Louis Provider of FDA-Cleared Device 2
... Nov. 26 The Providence Service,Corporation (Nasdaq: PRSC ... its financial advisor. , ... considering strategic,options relating to, among other things, delevering its debt, ... UBS,Investment Bank has been retained in connection with selling ...
... these products, experts say , , WEDNESDAY, Nov. 26 (HealthDay ... while at work may be more likely to have ... new report says. , Many cosmetics such as ... called phthalates, such as diethyl phthalate (DEP) and dibutyl ...
... Children whose eyes are misaligned and point outward ... illness by early adulthood, according to findings of ... Pediatrics ( http://pediatrics.aappublications.org/cgi/content/full/122/5/1033 ), the official ... The retrospective study examined the medical records of ...
... rural women, it,s cheaper and less time-consuming than ... News) -- Telephone counseling may be as effective as ... report. , The University of Florida study included 234 ... areas of northern Florida. , All the women completed ...
... engagement practitioners from across the world are to share ... held in South Africa, organised by the Wellcome Trust. ... to empower" will take place from 2-5 December ... KwaZulu-Natal. It will bring together practitioners working in the ...
... See Billion Dollar Increase in Value of Family Members Taking Care ... CHICAGO,Nov. 26 With the economy continuing it,s downward turn, ... ones in need. A new AARP report found the value ... than a $1 billion increase since 2006. While nearly 1.5 ...
Other Medicine News:Health News:Providence Service Corporation Retains UBS Investment Bank as its Financial Advisor in Connection With the Sale of Certain Non-Strategic Assets 2Health News:Over-the-Phone Weight Loss Counseling Works 2Health News:International workshop aims to boost public engagement work in developing countries 2Health News:International workshop aims to boost public engagement work in developing countries 3Health News:AARP Finds Value of Unpaid Family Caregiving in Illinois Hits $17 Billion 2
... OcularProtect is a scientifically ... support for visual and full ... 40 key nutrients, including a ... as FloraGLO lutein, lycopene and ...
... Most people take their eyes ... your body, your eyes need proper ... eye health and vision as you ... nutrition is critical to maintaining and ...
Easy-to-use desktop QC data management solution...
Non-Temperature Ablation Catheters...
Medicine Products: